GermanyGermany

EMA approves BF-200 ALA

15.12.2011

Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its drug for the treatment of actinic keratosis. There was no recommendation for a restriction or temporal limitation of the approval. The substance, which Biofrontera had dubbed BF-200 ALA while in development, will now be marketed under the name Ameluz. The positive assessment report by the Committee for Medicinal Products for Human Use (CHMP) will now be forwarded to the European Commission for the formal conclusion of the process. Biofrontera anticipates final approval in December. After that, Ameluz can be commercialised in all 27 countries of the EU as well as Norway, Iceland and Liechtenstein, the company stated. Biofrontera began the application process in September of 2010.

GermanyGermany

11.01.2011

Berlin – German biotech associations have strengthened their collaboration. The Heidelberg-based European Association of Pharma Biotechnology (EAPB) and Germany’s Biotechnology Industry Organisation Bio Deutschland e. V. said...

GermanyGermany

24.12.2010

European Biotechnology News wishes Merry Christmas and a Happy New Year! We will be back with daily news and a packed calendar on Monday 2nd January.

GermanyGermany

20.12.2010

Berlin/Dortmund – German researchers have identified potential targets involved in the formation of so called neutrophil extracellular traps (NETs), DNA-protein nets that are formed by cells of the innate immune system to defend...

GermanyGermany

16.12.2010

Heerlen/Leipzig – DSM Pharmaceutical Products, the custom manufacturing arm of Dutch Royal DSM NV, has licensed proprietary alcohol dehydrogenases from German enzyme specialist c-LEcta GmbH for enzyme screening programmes and...

GermanyGermany

09.12.2010

Dresden/Munich/Bethesda – German and US researchers from NIH and the universities Munich and Dresden have developed the first mouse model ever that exactly mimics human key symptoms of psoriasis. The mice developed the same...

GermanyGermany

07.12.2010

Göttingen/Paris – Researchers from Germany, Denmark and French BioAlliance Pharma S.A have found that reducing angiogenesis in xenotransplantation models of psoriasis and in mice with a disease that resembles psoriasis alleviates...

GermanyGermany

23.11.2010

Regensburg – During the unravelling of a transcriptional network in photoreceptors, German and US researchers have identified a novel gene that affects the inherited retinal disease Retinitis pigmentosa (type 28). In a...

Displaying results 61 to 70 out of 454

< Previous 61-70 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/6/article/ema-approves-bf-200-ala.html

Events

All Events

Stock list

All quotes

TOP

  • CO.DON2.84 EUR4.80%
  • VITA 343.98 EUR4.19%
  • MEDIGENE4.07 EUR2.26%

FLOP

  • THERAMETRICS0.08 CHF-11.11%
  • CYTOS0.24 CHF-4.00%
  • BASILEA97.25 CHF-1.22%

TOP

  • SANTHERA93.80 CHF46.3%
  • CO.DON2.84 EUR19.3%
  • FORMYCON8.22 EUR18.8%

FLOP

  • EVOTEC3.09 EUR-17.6%
  • MEDIGENE4.07 EUR-13.8%
  • 4SC1.16 EUR-12.8%

TOP

  • SANTHERA93.80 CHF2036.7%
  • CO.DON2.84 EUR226.4%
  • PAION2.69 EUR158.7%

FLOP

  • CYTOS0.24 CHF-94.0%
  • THERAMETRICS0.08 CHF-46.7%
  • MERCK KGAA67.56 EUR-41.3%

No liability assumed, Date: 15.09.2014


Current issue

All issues

Product of the week

Products